Funding for this research was provided by:
National Institute on Drug Abuse (R01DA034266)
Received: 23 January 2018
Accepted: 7 June 2018
First Online: 18 June 2018
Ethics approval and consent to participate
: The study was approved by the Principal Investigator’s Institutional Review Board (Federalwide Assurance Number: 00003425), and informed consent was received from all participants prior to data collection.
: Not applicable.
: Alkermes provided Vivitrol at no charge to certain patients participating in this study. This arrangement was disclosed and approved by the National Institutes of Health project officer. The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.